Ozempic, GLP-1s May Help Curb Substance Use Disorders, UTEP Study Finds Significantly lower rates of alcohol, nicotine, opioid and cocaine use disorders found among patients taking GLP-1 medications EL PASO, Texas (June 8, 2026) A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders
Five insights from the global burden of disease study 2019
Semaglutide's dual-action approach slows stomach emptying and signals early satiety in the brain, leading to reduced food intake and long-lasting appetite control
Discreet & protected Neutral packaging, temperature-controlled handling, and fully tracked delivery
Components: CJC-1295 (no DAC): 200mcg subcutaneous before bed Ipamorelin: 200mcg subcutaneous before bed Schedule: 5 days on, 2 days off